96 related articles for article (PubMed ID: 28903353)
1. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity.
Hato SV; Figdor CG; Takahashi S; Pen AE; Halilovic A; Bol KF; Vasaturo A; Inoue Y; de Haas N; Verweij D; Van Herpen CML; Kaanders JH; van Krieken JHJM; Van Laarhoven HWM; Hooijer GKJ; Punt CJA; Asai A; de Vries IJM; Lesterhuis WJ
Oncotarget; 2017 Aug; 8(33):54434-54443. PubMed ID: 28903353
[TBL] [Abstract][Full Text] [Related]
2. STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics.
de Haas N; de Koning C; di Blasio S; Flórez-Grau G; de Vries IJM; Hato SV
J Immunol Res; 2019; 2019():7458238. PubMed ID: 31309123
[TBL] [Abstract][Full Text] [Related]
3. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
4. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling.
Ahmad A; Sarkar SH; Aboukameel A; Ali S; Biersack B; Seibt S; Li Y; Bao B; Kong D; Banerjee S; Schobert R; Padhye SB; Sarkar FH
Carcinogenesis; 2012 Dec; 33(12):2450-6. PubMed ID: 22971573
[TBL] [Abstract][Full Text] [Related]
5. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.
Quintanilla-Martinez L; Kremer M; Specht K; Calzada-Wack J; Nathrath M; Schaich R; Höfler H; Fend F
Am J Pathol; 2003 May; 162(5):1449-61. PubMed ID: 12707028
[TBL] [Abstract][Full Text] [Related]
6. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Buettner R; Mora LB; Jove R
Clin Cancer Res; 2002 Apr; 8(4):945-54. PubMed ID: 11948098
[TBL] [Abstract][Full Text] [Related]
7. SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.
Duan Z; Bradner JE; Greenberg E; Levine R; Foster R; Mahoney J; Seiden MV
Clin Cancer Res; 2006 Nov; 12(22):6844-52. PubMed ID: 17121906
[TBL] [Abstract][Full Text] [Related]
8. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
9. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of STAT signaling in inflammation and tumorigenesis.
Adach A; Ellert-Miklaszewska A; Kaminska B
Methods Mol Biol; 2009; 512():265-78. PubMed ID: 19347282
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.
Hato SV; Khong A; de Vries IJ; Lesterhuis WJ
Clin Cancer Res; 2014 Jun; 20(11):2831-7. PubMed ID: 24879823
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma.
Bonner JA; Yang ES; Trummell HQ; Nowsheen S; Willey CD; Raisch KP
Radiother Oncol; 2011 Jun; 99(3):339-43. PubMed ID: 21704410
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
14. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
Zhang T; Ma J; Cao X
Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
[TBL] [Abstract][Full Text] [Related]
15. An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT.
Fujitani Y; Hibi M; Fukada T; Takahashi-Tezuka M; Yoshida H; Yamaguchi T; Sugiyama K; Yamanaka Y; Nakajima K; Hirano T
Oncogene; 1997 Feb; 14(7):751-61. PubMed ID: 9047382
[TBL] [Abstract][Full Text] [Related]
16. Guggulsterone (GS) inhibits smokeless tobacco and nicotine-induced NF-κB and STAT3 pathways in head and neck cancer cells.
Macha MA; Matta A; Chauhan SS; Siu KW; Ralhan R
Carcinogenesis; 2011 Mar; 32(3):368-80. PubMed ID: 21177768
[TBL] [Abstract][Full Text] [Related]
17. Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.
Szeląg M; Czerwoniec A; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2014 Oct; 740():417-20. PubMed ID: 25183399
[TBL] [Abstract][Full Text] [Related]
18. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells.
Saydmohammed M; Joseph D; Syed V
J Cell Biochem; 2010 May; 110(2):447-56. PubMed ID: 20235152
[TBL] [Abstract][Full Text] [Related]
19. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
